← FDA DRUG APPROVALS

FDA ANDA · ANDA040731

PHENYTOIN SODIUM

Sponsor: SUN PHARM INDS

APPLICATION
ANDA040731
TYPE
ANDA
ORIGINAL APPROVAL
2008-06-30
LATEST ACTION
2023-03-28
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

EXTENDED PHENYTOIN SODIUMDiscontinued
PHENYTOIN SODIUM 300MG EXTENDED · CAPSULE · ORAL
EXTENDED PHENYTOIN SODIUMDiscontinued
PHENYTOIN SODIUM 200MG EXTENDED · CAPSULE · ORAL

Approval history

2023-03-28Labeling · Supplement 24 · standardAP
2023-03-28Labeling · Supplement 20 · standardAP
2010-01-21Labeling · Supplement 2AP
2008-06-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →